Answers are grounded in this paper and cite their sources.
The GBG 26 — TBP study of the German Breast Group addressed the question of whether the treatment of women with HER2-positive metastatic breast cancer with trastuzumab is effective beyond progression (Trastuzumab Beyond Progression TBP). In this study, women with metastatic HER2-positive breast cancer who had progressed on prior trastuzumab treatment were treated either with a combination of trastuzumab (Herceptin(r), Roche Pharma AG, Grenzach-Whylen, Germany) and capecitabine (Xeloda(r), Roche Pharma AG) or capecitabine alone.
No takes yet. Share an insight, caveat, or question.
Pirvulescu et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: